Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 2/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | TOP2A | P11388 | 6/20 | 0.37 |
| ▸ | TOP1 | P11387 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | TOP2B | Q02880 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19728621 | 0.92 | TOP1 (0.34) | KDM4EHPGDCYP2C19STAT3TOP2A | |
| SCHEMBL19728616 | 0.91 | KDM4E (0.41) | KDM4EHPGDCYP2C19STAT3ADRB2 | |
| SCHEMBL19728835 | 0.90 | TOP1 (0.43) | KDM4EHPGDCYP2C19STAT3ADRB2 | |
| SCHEMBL19728610 | 0.90 | TOP2A (0.43) | TOP2ATOP1TOP2BKCNH2 | |
| SCHEMBL19729474 | 0.89 | STAT3 (0.40) | KDM4EHPGDCYP2C19STAT3ADRB2 | |
| SCHEMBL19728750 | 0.85 | STAT3 (0.38) | KDM4EHPGDCYP2C19STAT3ADRB2 | |
| SCHEMBL19729400 | 0.85 | KDM4E (0.45) | KDM4EHPGDCYP2C19STAT3ADRB2 | |
| SCHEMBL19728719 | 0.84 | STAT3 (0.38) | KDM4EHPGDCYP2C19STAT3ADRB2 | |
| SCHEMBL19728736 | 0.84 | STAT3 (0.38) | KDM4EHPGDCYP2C19STAT3ADRB2 | |
| SCHEMBL19728716 | 0.84 | TOP2A (0.42) | KDM4EHPGDTOP2ATOP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190276407-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2019-09-12 | — | — | US | disclosed |
| US-20190276407-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2019-09-12 | — | — | US | disclosed |
| EP-3473616-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | Wakunaga Pharmaceutical Co., Ltd. (JP) | 2019-04-24 | — | — | EP | disclosed |
| WO-2017217441-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | 湧永製薬株式会社 | 2017-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276407-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | CTR9, PYCR1, ACAD9 | KDM4E 2371/4885HPGD 598/4885CYP2C19 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.